<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-88346</identifier>
<setSpec>0300-2896</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Limitations of current treatment: unmet needs in the treatment of COPD</dc:title>
<dc:description xml:lang="en">In the last few years, considerable interest has been aroused in the treatment of chronic obstructive pulmonarydisease (COPD) and the dearth of therapeutic options has been replaced by a far more proactive treatmentapproach, reflected in the development of the various guidelines and recommendations of the scientific societies.There are three main steps in the treatment of COPD: prevention of the disease, treatment of its symptoms,progression and complications, and recovery of physical function through respiratory rehabilitation. Considerableadvances have been produced in these three dimensions, but limitations have been detected, indicating areas forimprovement. The most effective means to prevent the disease is smoking cessation. While there are moderatelyeffective drugs to help individuals quit, no drugs are available to prevent relapses. Moreover, due to healthpolicies, most patients with COPD do not receive drug treatment for smoking. The treatment of COPD and itscomplications is based on the use of bronchodilators, which improve symptoms and quality of life and, to agreater or lesser extent, prevent exacerbations. However, treatment aimed at the underlying pathogenic causesof the disease, which should be antiinflammatory treatment, remains an unresolved issue due to the discouragingresults obtained with inhaled corticosteroids, which should always be used in combination with a bronchodilator.The development of new antiinflammatory agents, such as roflumilast, could improve the management ofpatients with the most severe disease and repeated exacerbations. Lastly, although respiratory rehabilitation ishighly effective in helping patients recover their ability to exercise, few patients have access to this option. Aswith the treatment of smoking, there is a need to implement respiratory rehabilitation through simple andeffective programs and with the support of the health administration(AU)</dc:description>
<dc:creator>López Martín, Soledad</dc:creator>
<dc:creator>Lucas Ramos, Pilar de</dc:creator>
<dc:creator>Rodríguez González-Moro, José Miguel</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La aparición de nuevos antiinflamatorios, como el roflumilast, puede mejorar el manejo de los pacientes más graves y con repetidas exacerbaciones. Por último, aunque la rehabilitación respiratoria muestra una gran eficacia en la recuperación de la capacidad de ejercicio de los pacientes, son pocos los enfermos que pueden acceder a aquélla, y tal como ocurría con el tratamiento del tabaquismo, se detecta la necesidad de implementar suutilización a través de nuevos programas sencillos, eficaces y con apoyo de la administración sanitaria(AU)</dc:description>
<dc:source>Arch Bronconeumol;46(supl.10): 8-13, dic. 2010. ilus, tab</dc:source>
<dc:identifier>ibc-88346</dc:identifier>
<dc:title xml:lang="es">Limitaciones del tratamiento actual: necesidades no cubiertas en el tratamiento de la EPOC</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d906^s22073</dc:subject>
<dc:subject>^d23925^s22067</dc:subject>
<dc:subject>^d2021^s22073</dc:subject>
<dc:subject>^d36008^s22057</dc:subject>
<dc:subject>^d308^s22073</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d36008^s22061</dc:subject>
<dc:type>article</dc:type>
<dc:date>201012</dc:date>
</metadata>
</record>
</ibecs-document>
